Trial Profile
A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Oct 2022 Status changed from active, no longer recruiting to completed.
- 13 Jan 2021 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2021.
- 12 Dec 2018 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.